#ASH20: Or­ca’s team show­cas­es their first cut of the da­ta on promis­ing cell pu­rifi­ca­tion work for HSCT

For decades now hematopoi­et­ic stem-cell trans­plan­ta­tion has of­fered a risky, pos­si­bly life-threat­en­ing and some­times cu­ra­tive ef­fort for treat­ing hema­to­log­i­cal ma­lig­nan­cies.

Tak­ing some lessons from Irv Weiss­man’s lab at Stan­ford, up­start biotech Or­ca tweaked the stan­dard al­lo­gene­ic ap­proach us­ing donor stem cells, pu­ri­fy­ing the cells and tight­ly con­trol­ling vein-to-vein times among pa­tients. And they’re putting some im­pres­sive ear­ly re­sults on dis­play at ASH that they hope can help con­vince the FDA to al­low them to vault in­to a piv­otal tri­al soon.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER